PROACTIVEINVESTORS interview with CEO, Dr Sarah Howell re the dosing of Arecor’s first patient in its Phase I clinical trial of its rapid-acting insulin product candidate, AT247, for the improved treatment of diabetes.
Arecor, the specialty pharmaceutical company leveraging its innovative and proprietary formulation technology to develop superior treatments for a range of disease areas, including diabetes, announces the initiation of its AT247 Phase I clinical trial and an important next step in the Company’s strategy to develop even faster acting insulins targeted at improving treatment and health outcomes for people living with Type 1 diabetes.
Watch the interview here: